solid driven biosimilar even enbrel xgeva prolia continu show
robust steadi double-digit growth guidanc increas slightli revs/ep
otezla deal expect ye see solid total rev growth y/i ep y/i
pivot data lung cancer tezepelumab asthma expect
transit pipelin stori
rais pt roll valuat base multipl unchang
anticip multipl expand driven pipelin readout tezepelumab
asthma kra nsclc pipelin bispecif advanc toward
studi data heart failur omecamtiv mecarbil provid posit
upsid option support ep estim believ
conserv upsid
boost total rev leav ep estim unchang higher end
slightli rais guidanc total revs/ep align prior
estim make slight adjust model rais total rev
leav non-gaap ep unchang
even biosimilar show strong uptak rais estim account
view street continu underestim futur sale potenti even
overlook asset set receiv approv europ shortli approv
us japan grow biosimilar franchis even solid start post
third quarter market japan quarter us sale
mostli driven robust uptak japan ad even model
ramp sale also ad
biosimilar rituxan start model sale biosimilar franchis grow
view franchis under-appreci
growth driver sale
manag remain confid close deal ye impress
mani time manag note expect synergi otezla
busi unit includ inflamm franchis enbrel us amjevita
global addit otezla synergist grow inflamm busi
europ integr compon japanes strategi plan
assum full ownership jv astella
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long-term prospect
potenti data
studi lung cancer
data tezepelumab studi
data bite
data bite
data omecamtiv mecarbil
studi heart failur
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma earli stage oncolog pipelin solid liquid tumor
biosimilar franchis aimovig also provid attract growth venu
track break-out pivot nsclc data expect
call manag highlight pivot lung cancer studi enrol
briskli sinc initi aug anticip data releas studi
also ad expand arm drive decis futur pivot
develop pathway either mono combo
respect bar approv agent nsclc patient
fail cpi platinum manag necessarili agre pr
mo durabl right bogey hint even lower bar may suffic depend
data instead note advanc popul littl remain
option suggest monotherapi data determin whether drug provid
ampl therapeut benefit approv monotherapi given unmet need
final manag confirm satisfi pk profil qd
dose taken tablet without issu provid adequ hr coverag
view coval tki need high cmax first hr cover target
achiev part develop plan intend test dose
includ bid cover base
pivot test qd dose dose test like done
parallel aid select optim dose also combin therapi
delay time market assum qd provid ampl efficaci singl
agent nsclc
cowen compani
cowen compani
amgen quarterli model growth us ex-u growth y/i erythropoietin enbrel growth us ex-u sale g-csf growth us ex-u us ex-u dmab growth us ex-u kyproli growth us ex-u us ex-u us ex-u us ex-u growth probabl product sale growth revenu growth good sold margin margin product expensenet incom growth gaap growth share outstand cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
